Absci (ABSI)
Designs antibody drug candidates with generative AI and validates them in its own wet lab.
Something off on this page? Send us feedback.
Combines a generative AI model with an automated wet lab to design antibodies against disease targets that lack any known binder, then advances the strongest candidates through early clinical testing while licensing the platform to larger drug makers for milestone and royalty payments.
Antibody therapeutics are designed computationally with a generative model, then tested through an automated wet lab that feeds results back into the model. This cycle targets disease proteins with no existing known binder, a category traditional screening struggles to address.
Two tracks run in parallel. An internal pipeline led by an anti-PRLR antibody is in early clinical testing for androgenetic alopecia, with an endometriosis indication planned next. A second antibody for inflammatory bowel disease finished initial human testing and is offered to outside partners rather than advanced internally, alongside earlier oncology candidates.
Revenue comes mainly from platform partnerships with larger drug makers, which license the design technology against specific targets for upfront fees, research funding, and milestone and royalty payments.
Operations are concentrated in one automated research campus in Vancouver, Washington, built around pairing computational design with rapid physical validation.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | BTIG | Reiterate | Rating: —Target: $9 | Target: $15 |
| Jun 25, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $4.10 | Target: $10 |
| Jun 25, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $8 | Target: $16 |
| Jun 15, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $15 |
| Jun 4, 2026 | Leerink Partners | Target | Target: — | Target: $12 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $201.1M · Total debt $3.7M · Total assets $268.9M · Shareholders' equity $246.1M
- Revenue
- $318.0K
- Operating income
- −$34.2M
- Net income
- −$33.2M
No dividends on record.
| Institutions | ≈ 88.07% | 151.13M shares | |
|---|---|---|---|
| 208 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 7.63% | 13.09M shares | |
| 11 holders · as of Sep 1, 2026 | |||
| Other | ≈ 4.30% | 7.39M shares | |
| remainder | |||
171.61M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.81% | 25.41M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 7.53% | 12.93M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.09% | 12.18M | as of Jun 30, 2026 |
Sean McClain1Insiderdirector, officer: Chief Executive Officer | 6.63% | 11.00M | filed Jun 26, 2026 |
State Street CorpInstitution | 4.72% | 8.10M | as of Jun 30, 2026 |
- Sean McClain's transaction reports restate only vehicles that traded; the 2025 ownership statement (11.00M) plus the 373.6K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 30, 2026 | Mary T. Szela | director | +12,900 | $11.54 |
| May 13, 2026 | Menelas N. Pangalos | director | +37,453 | $5.36 |
| Mar 12, 2026 | Andreas Busch | officer: Chief Innovation Officer | +100,000 | $2.29 |
| Feb 27, 2026 | Menelas N. Pangalos | director | +75,095 | $2.74 |
| Feb 2, 2026 | Zachariah Jonasson | officer: CFO / CBO | −17,496 | $2.99 |
- Recursion Pharmaceuticals
Closest AI-native drug discovery platform peer, scaled by the Exscientia merger.
- AbCellera Biologics
Direct antibody-discovery platform peer with a large pharma partnership book.
- Relay Therapeutics
AI-native drug design platform, mostly small molecules.
- Codexis
ML-driven protein and enzyme engineering for pharma biomanufacturing.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Absci | $10.80 | +1.09% | $1.66B | — | — | 1,065.7 | −49.4% |
| Recursion Pharmaceuticals | $4.07 | +0.49% | $2.08B | — | — | 38.0 | −61.8% |
| AbCellera Biologics | $12.63 | −0.08% | $3.87B | — | — | 58.4 | −76.3% |
| Relay Therapeutics | $19.25 | −0.54% | $3.99B | — | — | 385.1 | −48.3% |
| Codexis | $1.40 | −0.36% | $148.4M | — | — | 1.9 | −2.7% |
| Median | — | — | 48.2 | −55.0% |